Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension

Circulation Journal

Volumn 70, Issue 8, 2006, Pages 1058-1063

  Reesink, Herre J ^a   Meijer, Ronald C ^a   Lutter, René ^a   Boomsma, Frans ^b   Jansen, Henk M ^a   Kloek, Jaap J ^a   Bresser, Paul ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic thromboembolic pulmonary hypertension; Endothelin 1; Pulmonary endarterectomy

Indexed keywords

ENDOTHELIN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY EMBOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDARTERECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG RESISTANCE; MALE; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS OXYGEN TENSION;

ADOLESCENT; ADULT; AGED; ENDARTERECTOMY; ENDOTHELIN-1; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY ARTERY; PULMONARY EMBOLISM; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 33746761646     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1058     Document Type: Article

References (33)

1. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.
2. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
3. Nakamura M, Okada O, Sakuma M, Nakanishi N, Miyahara Y, Yamada N, et al. Incidence and clinical characteristics of chronic pulmonary thromboembolism in Japan compared with acute pulmonary thromboembolism: Results of a multicenter registry of the Japanese Society of Pulmonary Embolism Research. Circ J 2002; 66: 257-260.
4. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
5. Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol Pharm Bull 2001; 24: 1219-1230.
6. Chang H, Wu GJ, Wang SM, Hung CR. Plasma endothelin levels and surgically correctable pulmonary hypertension. Ann Thorac Surg 1993; 55: 450-458.
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
8. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
9. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-1585.
10. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
11. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
12. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036.
13. McCulloch KM, Docherty CC, Morecroft I, MacLean MR. Endothelin-B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996; 119: 1125-1130.
14. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
15. Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: Appearance at angiography. Radiology 1992; 182: 393-398.
16. Viner SM, Bagg BR, Auger WR, Ford GT. The management of pulmonary hypertension secondary to chronic thromboembolic disease. Prog Cardiovasc Dis 1994; 37: 79-92.
17. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
18. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
19. American Thoracic Society. ATS statement: Guidelines for the sixmin walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
20. Mahrer JM, Magel RC. A comparison of tests for the k-sample, non-decreasing alternative. Stat Med 1995; 14: 863-871.
21. Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74: 180-184.
22. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
23. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237.
24. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000; 15: 640-648.
25. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128: 2363-2367.
26. Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 707.
27. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: Experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457-1462
28. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123: 338-343.
29. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 595-600.
30. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141.
31. Ono F, Nagaya N, Kyotani S, Oya H, Nakanishi N, Miyatake K. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 2003; 67: 375-378.
32. Kataoka M, Satoh T, Manabe T, Anzai T, Yoshikawa T, Mitamura H, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461-465.
33. Sasayama S, Kunieda T, Tomoike H, Matsuzaki M, Shirato K, Kuriyama T, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005; 69: 131-137.